CATAFLAM 50 Milligram Coated Tablets

Ireland - English - HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:
DICLOFENAC POTASSIUM
Available from:
Novartis Pharmaceuticals UK Ltd
ATC code:
M01AB05
INN (International Name):
DICLOFENAC POTASSIUM
Dosage:
50 Milligram
Pharmaceutical form:
Coated Tablets
Prescription type:
Product subject to prescription which may be renewed (B)
Therapeutic area:
Acetic acid derivatives and related substances
Authorization status:
Authorised
Authorization number:
PA0013/088/002
Authorization date:
1995-03-13

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Cataflam 50mg Coated Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 50mg diclofenac potassium.

Each tablet also contains 67mg sucrose.

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Coated tablet (Tablet)

Circular, biconvex, reddish brown sugar coated tablets approximately 8.8mm diameter.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Short-term treatment of all grades of pain and inflammation in the following acute conditions:

Post-traumatic pain, inflammation and swelling, e.g. due to sprains.

Acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendonitis, tenosynovitis,

bursitis.

Post operative pain, inflammation and swelling, e.g. following dental or orthopaedic surgery.

Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis and associated

menorrhagia.

Migraine attacks.

Acute gout

Painful syndromes of the vertebral column.

Non-articular rheumatism.

As an adjuvant in severe painful inflammatory infections of the ear, nose or throat, e.g. pharyngotonsillitis, otitis.

In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as

appropriate. Fever alone is not an indication.

4.2 Posology and method of administration

Undesirable effects may be minimised by using the lowest effective dose for the shortest

duration necessary to control

symptoms (see section 4.4).

The tablets should be swallowed whole with liquid, preferably before meals, and must not be divided or chewed.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

1

Adults

The recommended initial daily dose is 100 to 150 mg. In milder cases, 75 to 100 mg daily is usually sufficient.

The total daily dose should generally be divided in 2 to 3 doses.

In primary dysmenorrhoea, the daily dose should be individually adjusted and is generally 50 to 150 mg. A dose of 50

to 100 mg should be given initially and, if necessary, increased over the course of several menstrual cycles up to a

maximum of 200 mg/day. Treatment should be started on appearance of the first symptoms and, depending on the

symptomatology, continued for a few days.

In migraine, an initial dose of 50 mg should be taken at the first signs of an impending attack. In cases where pain relief

within 2 hours after the first dose is not sufficient, a further dose of 50 mg may be taken. If needed, further doses of 50

mg may be taken at intervals of 4 to 6 hours, not exceeding a total dose of 200 mg per day.

Children and adolescents:

Cataflam tablets are not recommended for use in children and adolescents below 14 years of age; other forms of

diclofenac such as oral drops or suppositories could be used in these patients. For adolescents aged 14 years and over, a

daily dose of 75 to 100 mg is usually sufficient. The total daily dose should generally be divided in 2 to 3 doses.

The maximum daily dose of 150 mg should not be exceeded

The use of Cataflam (all forms) in migraine attacks has not been established in children and adolescents.

Older people (Patients aged 65 or above)

Although the pharmacokinetics of Cataflam are not impaired to any clinically relevant extent in elderly patients, non-

steroidal anti-inflammatory drugs should be used with particular caution in older patients who generally are more prone

to adverse reactions.

In particular, it is recommended that the lowest effective dosage be used in frail elderly patients

or those with a low body weight (see also precautions).

Treatment should be reviewed at regular intervals and discontinued if no benefit is seen or if intolerance occurs

Renal impairment

Diclofenac is contraindicated in patients with severe renal impairment (see section 4.3).

No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment

recommendations can be made.

Caution is advised when administering diclofenac to patients with mild to moderate renal impairment (see section 4.3

and 4.4).

Hepatic impairment

Diclofenac is contraindicated in patients with severe hepatic impairment (see section 4.3).

No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment

recommendations can be made.

Caution is advised when administering diclofenac to patients with mild to moderate hepatic impairment (see section 4.3

and 4.4).

4.3 Contraindications

Known hypersensitivity to the active substance or to any of the excipients.

Active gastric or intestinal ulcer, bleeding or perforation

History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Active or history of

recurrent peptic ulcer/ haemorrhage (two or more distinct episodes of proven ulceration or bleeding).

Last trimester of pregnancy (see section 4.6 Pregnancy and lactation).

Hepatic failure

Chronic Kidney Disease Grade 5 (GFR <15)

Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease and/or

cerebrovascular disease.

Like other non-steroidal anti-inflammatory drugs (NSAIDs), Cataflam is also contraindicated in patients in

whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

2

4.4 Special warnings and precautions for use

General

Undesirable effects may be minimised by using the lowest effective dose for the shortest possible duration necessary to

control symptoms (see section 4.2 Posology and GI and cardiovascular risks below).

The use of Cataflam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors, should be avoided due

to the absence of any evidence demonstrating synergistic benefits and the potential for additive undesirable effects.

Caution is indicated in the elderly on basic medical grounds. In particular it is recommended that the lowest effective

dosage be used in frail elderly patients or those with a low body weight.

Like other NSAIDs, Cataflam may mask the signs and symptoms of infection due to its pharmacodynamic properties.

Cataflam tablets contain sucrose and therefore are not recommended for patients with rare hereditary problems of

fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.

The use of diclofenac potassium may impair female fertility and is not recommended in women attempting to conceive.

In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of diclofenac

potassium should be considered.

Gastrointestinal effects

Gastrointestinal bleeding or ulceration or perforation, which can be fatal, have been reported with all NSAIDs,

including diclofenac, and may occur at any time during treatment, with or without warning symptoms or a previous

history of serious gastrointestinal events. The elderly have an increased frequency of adverse reactions to NSAIDs

especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2 Posology and method of

administration) When gastrointestinal bleeding or ulceration occur in patients receiving Cataflam, the medicinal

product should be withdrawn.

As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular caution should be

exercised when prescribing Cataflam in patients with symptoms indicative of gastrointestinal (GI) disorders or with a

history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8 Undesirable effects). The

risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer,

particularly if complicated with haemorrhage or perforation (see 4.3 Contra-indications) The elderly have an increased

frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.

To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with haemorrhage or

perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.

Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these

patients, and also for patients requiring concomitant use of medicinal products containing low-dose acetylsalicylic acid

(ASA)/aspirin or other medicinal products likely to increase gastrointestinal risk (see below and section 4.5 Interactions

with other medicinal products and other forms of interaction).

Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms

(especially GI bleeding) particularly in the early stages of treatment. Caution is recommended in patients receiving

concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids,

anticoagulants such as warfarin, anti-platelet agents such as aspirin or selective serotonin-reuptake inhibitors (see

section 4.5 Interaction with other medicinal products and other forms of interaction).

Close medical surveillance and caution should also be exercised inpatients with ulcerative colitis or Crohn’s disease),

as their condition may be exacerbated (see section 4.8 Undesirable effects).

Cardiovascular and cerebrovascular effects

Appropriate monitoring and advice are required for patients with a history of hypertension and/or congestive heart

failure (NYHA-1) as fluid retention and oedema have been reported in association with NSAID therapy.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

3

Clinical trial and epidemiological data suggest that the use of diclofenac, particularly at high doses (150 mg daily) and

in long term treatment may be associated with a small increased risk of arterial thrombotic events (for example

myocardial infarction or stroke).

Patients with congestive heart failure (NYHA-1) and patients with significant risk factors for cardiovascular events

(e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with diclofenac after careful

consideration. As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest

duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and

response to therapy should be re-evaluated periodically.

Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g. chest pain, shortness

of breath, weakness, slurring of speech), which can occur without warnings. Patients should be instructed to see a

physician immediately in case of such an event.

Hepatic effects

Close medical surveillance is required when prescribing Cataflam to patients with impaired hepatic function,

as their

condition may be exacerbated.

As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During prolonged

treatment with Cataflam, regular monitoring of hepatic function is indicated as a precautionary measure. If abnormal

liver function tests persist or worsen, if clinical signs or symptoms consistent with liver disease develop, or if other

manifestations occur (e.g. eosinophilia, rash etc), Cataflam should be discontinued. Hepatitis may occur with use of

diclofenac without prodromal symptoms.

Caution is called for when using Cataflam in patients with hepatic porphyria, since it may trigger an attack.

Renal effects

As fluid retention and oedema have been reported in association with NSAID therapy, including diclofenac, particular

caution is called for in patients with impaired cardiac or renal function , history of hypertension .the elderly, patients

receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and

in those patients with substantial extracellular volume depletion from any cause, e.g. before or after major surgery (see

section 4.3 Contraindications). Monitoring of renal function is recommended as a precautionary measure when using

diclofenac in such cases. Discontinuation of therapy is usually followed by recovery to the pre-treatment state.

Skin Effects

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic

epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including Cataflam (see

section 4.8 Undesirable effects). Patients appear to be at highest risk of these reactions early in the course of therapy,

the onset of the reaction occurring in the majority of cases within the first month of treatment. Cataflam should be

discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. As with other

NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur in rare cases with diclofenac

without earlier exposure to the drug.

Haematological effects

Use of Cataflam is recommended only for short-term treatment. If, however, Cataflam is used for a prolonged period,

monitoring of the blood count is recommended, as with other NSAIDs.

Like other NSAIDs, Cataflam may temporarily inhibit platelet aggregation. Patients with defects of haemostasis should

be carefully monitored.

Pre-existing asthma

In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive

pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms),

reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics/analgesics-asthma), Quincke’s

oedema or urticaria are more frequent than in other patients.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

4

Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well for

patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria.

4.5 Interaction with other medicinal products and other forms of interaction

The following interactions include those observed with Cataflam sugar-coated tablets and/or other pharmaceutical

forms of diclofenac.

Potent CYP2C9 inhibitors: Caution is recommended when co-prescribing diclofenac with potent CYP2C9 inhibitors

(such as voriconazole), which could result in a significant increase in peak plasma concentrations and exposure to

diclofenac due to inhibition of diclofenac metabolism.

Lithium: If used concomitantly, diclofenac may raise plasma concentrations of lithium Monitoring of the serum

lithium level is recommended.

Digoxin: If used concomitantly, diclofenac may raise plasma concentrations of digoxin .Monitoring of the serum

digoxin level is recommended.

Diuretics and antihypertensive agents: Like other NSAIDs, concomitant use of diclofenac with diuretics or

antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in

their antihypertensive effect. Therefore, the combination should be administered with caution and patients, especially

the elderly, should have their blood pressure periodically monitored. Patients should be adequately hydrated and

consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically

thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity. (see section 4.4

Special warnings and precautions for use).

Ciclosporin: Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the effect on renal

prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving

ciclosporin.

Drugs known to cause hyperkalemia: Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus

or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored

frequently (see section 4.4 Special warnings and precautions for use).

Quinolone antibacterials: There have been isolated reports of convulsions which may have been due to concomitant

use of quinolones and NSAIDs.

Anticipated Interactions to be considered

Other NSAIDs and corticosteroids: Concomitant administration of diclofenac and other systemic NSAIDs or

corticosteroids may increase the risk of gastrointestinal ulceration or bleeding (see section 4.4 Special warnings and

precautions for use)

Anticoagulants and anti-platelet agents: Caution is recommended since concomitant administration could increase the

risk of gastrointestinal bleeding (see section 4.4 Special warnings and special precautions for use). Although clinical

investigations do not appear to indicate that diclofenac affects the action of anticoagulants , NSAIDs may enhance the

effects of anti-coagulants, such as warfarin (see section 4.4.). There are also reports of an increased risk of haemorrhage

in patients receiving diclofenac and anticoagulants concomitantly .Close monitoring of such patients is therefore

recommended.

Selective serotonin reuptake inhibitors (SSRIs): Concomitant administration of systemic NSAIDs, including

diclofenac, and SSRIs may increase the risk of gastrointestinal bleeding (see section 4.4 Special warnings and

precautions for use).

Antidiabetics: Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents without

influencing their clinical effect. However, there have been isolated reports of both hypoglycaemic and hyperglycaemic

effects necessitating changes in the dosage of the antidiabetic agents during treatment with diclofenac.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

5

For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant

therapy.

Methotrexate: Diclofenac can inhibit the tubular renal clearance of methotrexate hereby increasing methotrexate

levels.Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before or after

treatment with methotrexate, since blood concentrations of methotrexate may rise and the toxicity of this substance be

increased

Colestipol and cholestyramine: These agents can induce a delay or decrease in absorption of diclofenac. Therefore, it

is recommended to administer diclofenac at least one hour before or 4 to 6 hours after administration of colestipol/

cholestyramine.

Phenytoin: When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is

recommended due to an expected increase in exposure to phenytoin

4.6 Fertility, pregnancy and lactation

Pregnancy

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data

from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis

after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation

was increased from less than 1%, up to approximately 1.5 %.

The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin

synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality.

In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals

given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of

pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to

conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of

treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose

the foetus to:

cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);

renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at

the end of pregnancy, to:

possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.

inhibition of uterine contractions resulting in delayed or

prolonged labour.

Consequently, diclofenac is contraindicated during the third trimester of pregnancy.

Lactation

Like other NSAIDs, diclofenac passes into the breast milk in small amounts. Therefore, Cataflam should not be

administered during breast feeding in order to avoid undesirable effects in the infant.

Fertility

As with other NSAIDs, the use of Cataflam may impair female fertility and is not recommended in women attempting

to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal

of Cataflam should be considered.

4.7 Effects on ability to drive and use machines

Patients who experience dizziness, vertigo, somnolence or other central nervous system disturbances, including visual

disturbances, while taking NSAIDs should refrain from driving or using machines.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

6

4.8 Undesirable effects

Adverse drug reactions from clinical trials and/or spontaneous or literature cases (Table 1) are listed by MedRA system

order class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent

reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing

seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on using the

following convention: (CIOMS III): very common (>1/10); common (

1/100, < 1/10); uncommon (

1/1,000, <

1/100); rare (

1/10,000, < 1/1,000); very rare (<1/10,000).

The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding,

sometimes fatal, particularly in the elderly, may occur (see section 4.4 Special warnings and precautions for use).

Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative

stomatitis, exacerbation of coilitis and Crohn’s disease (see section 4.4 Special warnings and precautions for use) have

been reported following administration. Less frequently, gastritis has been observed.

The following table of undesirable effects include those reported with Cataflam sugar-coated tablets and/or other

pharmaceutical forms of diclofenac, with either short-term or long-term use.

Table 1

Blood and lymphatic system disorders

Very rare:

Thrombocytopenia,

leucopenia,

anemia

(including

haemolytic

anemia

aplastic

anemia),

agranulocytosis.

Immune system disorders

Rare:

Hypersensitivity,

anaphylactic

anaphylactoid

reactions (including hypotension and shock)

Very rare:

Angionedema (including face edema).

Psychiatric disorders

Very rare:

Disorientation,

depression,

insomnia,

nightmare,

irritability, psychotic disorder.

Nervous system disorders

Common:

Headache, dizziness

Rare:

Somnolence

Very rare:

Paraesthesia,

memory impairment,

convulsion,

anxiety,

tremor,

meningitis

aseptic,

dysgeusia,

cerebrovascular

accident.

Eye disorders

Very rare:

Visual impairment, vision blurred, diplopia

Ear and labyrinth disorders

Common:

Vertigo

Very rare:

Tinnitus, hearing impaired

Cardiac disorders

Uncommon*:

Myocardial infarction, cardiac failure, palpitations, chest

pain

Vascular disorders

Very rare:

Hypertension, vasculitis.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

7

* The frequency reflects data from long-term treatment with a high dose (150 mg/day).

Clinical trial and epidemiological data consistently point towards an increased risk of arterial thrombotic events (for

example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high doses (150 mg

daily) and in long term treatment (see section 4.3 and 4.4 for Contraindications and Special warnings and special

precautions for use).

Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.

Respiratory, thoracic and mediastinal disorders

Rare:

Asthma/bronchospasm (including dyspnea).

Very rare:

Pneumonitis.

Gastrointestinal disorders

Common:

Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain,

flatulence, decreased appetite

Rare:

Gastritis,

gastrointestinal

hemorrhage,

Hematemesis,

diarrhea

hemorrhagic,

melena,

gastrointestinal

ulcer

(with or without bleeding or perforation)

Very rare:

Colitis (including hemorrhagic colitis and exacerbation

ulcerative colitis or

Crohn’s disease),

constipation,

stomatitis

(including

ulcerative

stomatitis),

glossitis,

oesophageal

disorder,

diaphragm-like

intestinal

strictures, pancreatitis

Not known:

Ischemic colitis

Hepatobiliary disorders

Common:

Transaminases increased.

Rare:

Hepatitis, jaundice liver disorder

Very rare:

Hepatitis fulminant, hepatic necrosis, hepatic failure

Skin and subcutaneous tissue disorders

Common:

Rash

Rare:

Urticaria.

Very rare:

Dermatitis

bullous,

eczema,

erythema,

erythema

multiforme, Stevens-Johnson syndrome, toxic epidermal

necrolysis

(Lyell's

syndrome),

dermatitis

exfoliative,

alopecia,

photosensitivity reaction,

purpura,

Henoch-

Schonlein purpura, pruritus

Renal and urinary disorders

Very rare:

Renal

failure

acute,

hematuria,

proteinuria,

nephritic

syndrome,

tubulointerstitial

nephritis,

renal

papillary

necrosis

General disorders and administration site conditions

Rare:

edema

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

8

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued

monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any

suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;

Fax: +353 1 6762517. Website: www.hpra.ie; e-mail: medsafety@hpra.ie.

4.9 Overdose

Symptoms

There is no typical clinical picture resulting from diclofenac overdosage. Overdosage can cause symptoms such as

vomiting, gastrointestinal haemorrhage, diarrhoea, dizziness, tinnitus or convulsions. In the event of significant

poisoning, acute renal failure and liver damage are possible.

Therapeutic measures

Management of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and

symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as

hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression.

Special measures such as forced diuresis, dialysis or haemoperfusion are probably unlikely to be helpful in accelerating

the elimination of NSAIDs, including diclofenac, due to the high protein binding and extensive metabolism

Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric decontamination (e.g.

vomiting, gastric lavage) after ingestion of a potentially life-threatening overdose.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, acetic acid derivatives and

related substances (ATC code: M01A B05).

Mechanism of action

Cataflam contains the potassium salt of diclofenac, a non-steroidal compound with pronounced analgesic, anti-

inflammatory and antipyretic properties. Inhibition of prostaglandin biosynthesis, which has been demonstrated in

experiments, is considered to be fundamental to its mechanism of action. Prostaglandins play a major role in causing

inflammation, pain and fever.

Cataflam tablets have a rapid onset of action which makes them particularly suitable for the treatment of acute painful

and inflammatory conditions.

Diclofenac potassium in vitro does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to

those reached in humans.

Pharmacodynamic effects

Cataflam has been found to exert a pronounced analgesic effect in moderate and severe pain. In the presence of

inflammation, e.g. due to trauma or following surgical interventions, it rapidly relieves both spontaneous pain and pain

on movement and diminishes inflammatory swelling and wound oedema.

Clinical studies have also revealed that in primary dysmenorrhoea the active substance is capable of relieving the pain

and reducing the extent of bleeding.

In migraine attacks Cataflam has been shown to be effective in relieving the headache and in improving the

accompanying symptoms of nausea and vomiting.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

9

There is limited clinical trial experience of the use of diclofenac in Juvenile Rheumatoid Arthritis (JRA)/Juvenile

Idiopathic Arthritis (JIA) paediatric patients. In a randomized, double-blind, 2-week, parallel group study in children

aged 3-15 years with JRA/JIA, the efficacy and safety of daily 2-3 mg/kg BW diclofenac was compared with

acetylsalicylic acid (ASS, 50-100 mg/kg BW/d) and placebo – 15 patients in each group. In the global evaluation, 11 of

15 diclofenac patients, 6 of 12 aspirin and 4 of 15 placebo patients showed improvement with the difference being

statistically significant (p < 0.05). The number of tender joints decreased with diclofenac and ASS but increased with

placebo. In a second randomized, double-blind, 6-week, parallel group study in children aged 4-15 years with JRA/JIA,

the efficacy of diclofenac (daily dose 2-3 mg/kg BW, n=22) was comparable with that of indomethacin (daily dose 2-

3mg/kg BW, n=23).

5.2 Pharmacokinetic properties

Absorption:

Diclofenac is rapidly and completely absorbed from diclofenac potassium tablets.

The absorption sets in immediately

after administration and the same amount is absorbed as from an equivalent dose of diclofenac sodium gastro-resistant

tablets.

Mean peak plasma concentrations of 3.8micromol/L are attained after 20 - 60 minutes after ingestion of one

tablet of 50mg.

Ingestion together with food has no influence on the amount of diclofenac absorbed although onset and

rate of absorption may be slightly delayed.

Since about half of diclofenac is metabolized during its first passage through the liver ("first pass" effect), the area

under the concentration curve (AUC) is about half as large following oral or rectal administration as it is following a

parenteral dose of equal size.

The amount absorbed is in linear proportion to the size of the dose.

Pharmacokinetic behaviour does not change after repeated administration.

No accumulation occurs provided the

recommended dosage intervals are observed.

Distribution:

The active substance is 99.7% protein bound, mainly to albumin (99.4%).

Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after peak plasma values

have been attained.

The apparent half-life for elimination from the synovial fluid is 3-6 hours.

Two hours after

reaching the peak plasma values, concentrations of the active substance are already higher in the synovial fluid than

they are in the plasma, and remain higher for up to 12 hours.

Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The estimated

amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose.

Biotransformation/Metabolism:

Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by single and

multiple hydroxylation and methoxylation, resulting in several phenolic metabolites, most of which are converted to

glucuronide conjugates.

Two phenolic metabolites are biologically active, but to a much lesser extent than diclofenac.

Elimination:

Total systemic clearance of diclofenac in plasma is 263 ± 56mL/min (mean value SD).

The terminal half-life in

plasma is 1-2 hours.

Four of the metabolites, including the two active ones, also have short plasma half-lives of 1-3

hours.

About 60% of the administered dose is excreted in the urine as the glucuronide conjugate of the intact molecule and as

metabolites, most of which are also converted to glucuronide conjugates.

Less than 1% is excreted as unchanged

substance.

The rest of the dose is eliminated as metabolites through the bile in the faeces.

Special Populations:

No relevant age-dependent differences in the drug’s absorption, metabolism, or excretion have been observed.

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

1

0

Patients with renal impairment: In patients suffering from renal impairment, no accumulation of the unchanged active

substance can be inferred from the single-dose kinetics when applying the usual dosage schedule.

At a creatinine

clearance of <10mL/min, the calculated steady-state plasma levels of the hydroxy metabolites are about 4 times higher

than in normal subjects.

However, the metabolites are ultimately cleared through the bile.

Patients with hepatic disease: In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and

metabolism of diclofenac are the same as in patients without liver disease.

5.3 Preclinical safety data

Preclinical data from acute and repeated dose toxicity studies, as well as from genotoxicity, mutagenicity, and

carcinogenicity studies with diclofenac revealed no specific hazard for humans at the intended therapeutic doses. In

standard preclinical animal studies, there was no evidence that diclofenac had a teratogenic potential in mice, rats or

rabbits.

Diclofenac had no influence on the fertility of parent animals in rats. Except for minimal fetal effects at maternally

toxic doses the prenatal, perinatal, and postnatal development of the offspring was not affected.

Administration of NSAIDs (including diclofenac) inhibited ovulation in the rabbit and implantation and placentation in

the rat, and led to premature closure of the ductus arteriosus in the pregnant rat. Maternally toxic doses of diclofenac

were associated with dystocia, prolonged gestation, decreased fetal survival, and intrauterine growth retardation in rats.

The slight effects of diclofenac on reproduction parameters and delivery as well as constriction of the ductus arteriosus

in utero are pharmacologic consequences of this class of prostaglandin synthesis inhibitors (see sections 4.3

Contraindications and 4.6 Fertility, pregnancy and lactation).

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core:

Colloidal anhydrous silica

Calcium phosphate

Magnesium stearate

Maize starch

Povidone K30

Sodium starch glycolate (Type A)

Coating and Polish:

Microcrystalline cellulose

Macrogol 8000

Crystalline sucrose

Povidone

Dispersed red (which consists of titanium dioxide (E171) and red iron oxide (E172).

Talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

1

1

6.4 Special precautions for storage

Do not store above 30

Store in the original package.

6.5 Nature and contents of container

PVC/PE/PVDC film on aluminium foil blister strips, 10 tablets/strip.

Pack sizes: 10 (sample pack), 20 or 30 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from

such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Novartis pharmaceuticals UK Limited,

Frimley Business Park,

Frimley, Camberley,

Surrey GU16 7SR,

United Kingdom.

8 MARKETING AUTHORISATION NUMBER

PA0013/088/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 13 March 1995

Date of last renewal:

25 July 2008

10 DATE OF REVISION OF THE TEXT

October 2016

H

e

a

l

t

h

P

r

o

d

u

c

t

s

R

e

g

u

l

a

t

o

r

y

A

u

t

h

o

r

i

t

y

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

D

a

t

e

P

r

i

n

t

e

d

0

9

/

0

2

/

2

0

1

8

C

R

N

2

1

9

6

8

5

0

p

a

g

e

n

u

m

b

e

r

:

1

2

Similar products

Search alerts related to this product

View documents history

Share this information